Actelion's Founders Start New Biotech, With J&J's Backing

Mar 02, 2017 - The Wall Street Journal
Jean-Paul and Martine Clozel, founders of Swiss biotech company Actelion, which has been sold to J&J, are starting over again. The husband and wife team is embarking on the creation of a new global biotech player—armed with nearly $1 billion in capital, a deep-pocketed partner in J&J and soon, a stock listing in Zurich. Read More